BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22027544)

  • 1. Medulloblastomas in adults: prognostic factors and lessons from paediatrics.
    Fellay CN; Frappaz D; Sunyach MP; Franceschi E; Brandes AA; Stupp R
    Curr Opin Neurol; 2011 Dec; 24(6):626-32. PubMed ID: 22027544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
    Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
    J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of gamma-catenin expression with good prognosis in medulloblastomas.
    Misaki K; Marukawa K; Hayashi Y; Fukusato T; Minamoto T; Hasegawa M; Yamashita J; Fujisawa H
    J Neurosurg; 2005 Mar; 102(2 Suppl):197-206. PubMed ID: 16156230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid diagnosis of medulloblastoma molecular subgroups.
    Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
    Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medulloblastomas: update on a heterogeneous disease.
    Bourdeaut F; Miquel C; Alapetite C; Roujeau T; Doz F
    Curr Opin Oncol; 2011 Nov; 23(6):630-7. PubMed ID: 21892087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours.
    Goschzik T; Zur Mühlen A; Kristiansen G; Haberler C; Stefanits H; Friedrich C; von Hoff K; Rutkowski S; Pfister SM; Pietsch T
    Neuropathol Appl Neurobiol; 2015 Feb; 41(2):135-44. PubMed ID: 24894640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medulloblastoma molecular dissection: the way toward targeted therapy.
    Remke M; Ramaswamy V; Taylor MD
    Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
    Clifford SC; Lusher ME; Lindsey JC; Langdon JA; Gilbertson RJ; Straughton D; Ellison DW
    Cell Cycle; 2006 Nov; 5(22):2666-70. PubMed ID: 17172831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
    Gajjar A; Hernan R; Kocak M; Fuller C; Lee Y; McKinnon PJ; Wallace D; Lau C; Chintagumpala M; Ashley DM; Kellie SJ; Kun L; Gilbertson RJ
    J Clin Oncol; 2004 Mar; 22(6):984-93. PubMed ID: 14970185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.
    Fattet S; Haberler C; Legoix P; Varlet P; Lellouch-Tubiana A; Lair S; Manie E; Raquin MA; Bours D; Carpentier S; Barillot E; Grill J; Doz F; Puget S; Janoueix-Lerosey I; Delattre O
    J Pathol; 2009 May; 218(1):86-94. PubMed ID: 19197950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
    von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
    Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
    Pizer BL; Clifford SC
    Br J Neurosurg; 2009 Aug; 23(4):364-75. PubMed ID: 19637007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
    Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
    J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological and molecular heterogeneity of medulloblastoma.
    Gulino A; Arcella A; Giangaspero F
    Curr Opin Oncol; 2008 Nov; 20(6):668-75. PubMed ID: 18841049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.
    Grotzer MA; von Hoff K; von Bueren AO; Shalaby T; Hartmann W; Warmuth-Metz M; Emser A; Kortmann RD; Kuehl J; Pietsch T; Rutkowski S
    Klin Padiatr; 2007; 219(6):312-7. PubMed ID: 18050040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile.
    Sadighi Z; Vats T; Khatua S
    J Child Neurol; 2012 Oct; 27(10):1302-7. PubMed ID: 22826514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
    Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
    Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medulloblastoma in the age of molecular subgroups: a review.
    Juraschka K; Taylor MD
    J Neurosurg Pediatr; 2019 Oct; 24(4):353-363. PubMed ID: 31574483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification.
    Polkinghorn WR; Tarbell NJ
    Nat Clin Pract Oncol; 2007 May; 4(5):295-304. PubMed ID: 17464337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.